Replies to post #181909 on Enzolytics Inc (ENZC)

[DOGONE]

Very good post DRHUMI....The MAKEWHOLE agreement insures we get the $450 mil worth of shares which is 90% of SAGA, no matter what. This tells me that ENZC, per the deal is worth 4.5 billion bucks! So SAGA knows more of what is happening behind the scenes than we do. Its a great deal and secures our holdings of ENZC. The final share structure will be determined by the share price after 6 months following the transaction date, as you stated. I also believe the transaction will be by the end of this month. After the 6 month period ends, I also feel that the NDAs will be revealed to all the SAGA share holders. So if we have a licensing agreement with REGENERON (which I feel we do) for the immutable sites for COVID, or other major pharmas for our other cures and mabs sites,, then that will launch us in value by who knows how much , leaving $10 a share in the dust. My guess is that there will be a lot of behind the scenes deals shown to us then.

[foxi]

I looked at the example deal again, and I don't think what you said matches what ENZC is telling us.


From Supplemental Information - Supplemental Information published 7/11:
https://www.otcmarkets.com/otcapi/company/financial-report/376167/content

The management of BGEN and VIRO will continue to manage the two subs as wholly owned subsidiaries of SAGA

The issuance of the Purchase Shares to Company E will result in a 90% plus ownership position of Company S until the Purchase Shares are paid as a dividend to the shareholders of Company E.

[regarding any Make-Whole bonus shares] The additional shares would be allocated proportionately to the holders of Company E’s common shares on the declared dividend date.

After the dividend to Company E shareholders, there would be no assets or operations in Company E,

It appears ENZC is indeed attempting to sell all its tech, which has been disclosed in ENZC's prior OTC markets filings as being retained fully in ENZC subsidiaries BGEN and VIRO, to SAGA. The valuation of BGEN and VIRO is $450M, not $4.5B, which does come out to 15 cents a share.

BGEN and VIRO would become SAGA's wholly owned subsidiaries. Whoever's at the top of the chain at SAGA would ultimately control ENZC IP, licensing, partnerships, and operations, except for what SAGA delegates to BGEN and VIRO management (ENZC's current management team).

As the deal is currently proposed, ENZC would have no assets and no operations remaining after the acquisition. (Technically they'd have RobustoMed, which would have zero assets and need a new business plan.)

There's nothing implying Sagaliam would rename itself. Investors would collect dividend shares one time; they would not collect 10% revenue until the end of time.

I'd give you more than one post a day if I had the ability, would love to hear your additional thoughts.